[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638493":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":24,"locations":29,"responsibleParty":60,"collaborators":63,"id":65,"slug":10,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":76,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic Test: Single Group Assignment",null,"Each subject receive a single intravenous injection of 68Ga\u002F18F-DMP10 or other PD-L1 tracers, and undergo PET\u002FCT imaging within the specificed time.",[9],[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Single Group Assignment","Each subject receive a single intravenous injection of 68Ga\u002F18F-DMP10 or other PDL1 tracers, and undergo PET\u002FCT imaging within the specificed time.",[9],[20],{"name":21,"affiliation":22,"role":23},"Haonan Yu, MD","Tianjin Medical University General Hospital","PRINCIPAL_INVESTIGATOR",[25],{"name":21,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+8613821000597","dreamadam@126.com",[30,48],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"The First Affiliated Hospital of University of Science and Technology of China","RECRUITING","Hefei","Anhui","230000","China",{"type":38,"coordinates":39},"Point",[40,41],117.28083,31.86389,{"lat":41,"lon":40},[44],{"name":45,"role":26,"phone":46,"phoneExt":10,"email":47},"Qiang Xie, PhD","+8613721108043","ahxq1980@163.com",{"facility":22,"status":32,"city":49,"state":50,"zip":51,"country":36,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Tianjin","Tianjin Municipality","300052",{"type":38,"coordinates":53},[54,55],117.17667,39.14222,{"lat":55,"lon":54},[58],{"name":59,"role":26,"phone":27,"phoneExt":10,"email":28},"Haonan Yu",{"type":23,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Shaobo Yao, PhD","Prof.",[64],{"name":22,"class":6},"100638493",false,"NCT07618936","Programmed Cell Death Ligand 1 PET\u002FCT in Various PD-L1-Related Disease Patients","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PD-L1 PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","ALL","18 Years","80 Years",{"count":74,"type":75},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga\u002F18F-PD-L1 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various PD-L1-related disease patients",[80,81,82,83],"PD-L1 Gene Mutation","PD-L1 Gene Amplification","PD-L1-related Disease","Positron Emission Tomography",[85,86,87],"PET\u002FCT","PD-L1","DMP10","2026-05-24",{"date":90,"type":91},"2026-06-01","ACTUAL",{"date":90,"type":75},{"date":94,"type":75},"2031-06-01",{"name":5,"class":6},2]